An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

Protocol: 
AAAS0000
Phase: 
I/II

An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

The purpose of this research study is to learn more about an experimental
personalized vaccine that has two components called GRT-C901 and GRT-R902.
We will learn more about the effects of this vaccine on your cancer when
used together with approved medications that activate the immune system,
nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are approved by the
United States Food and Drug Administration (FDA). The vaccine is specific to
you and your tumor, and cannot be used to treat any other patients.

Are you Eligible? (Inclusion Criteria)

-Do you have bladder, colon stomach, lung, esophageal, or rectal cancer?

-Do you have tumor tissue already available for testing?

-Are you willing to undergo biopsies prior to receiving study treatment and
also while receiving study treatment?

-Are you 18 years of age or older?

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States